Overview

* Sana Biotechnology ( SANA ) Q3 net loss of $42.2 mln, with operating expenses of $43.5 mln

* Raised $115.8 mln from stock sales, cash position at $153.1 mln

* Company prioritizes SC451 and SG293, suspends other CAR T programs

Result Drivers

* TYPE 1 DIABETES FOCUS - Sana prioritizes SC451 development due to promising clinical results and regulatory progress

* R&D expenses were $35.5 million for the three ended September 30, 2025, compared to $12.4 million for the same periods in 2024

*

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$42.15

Income mln

Q3 $43.52

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sana Biotechnology Inc ( SANA ) is $8.00, about 49% above its November 5 closing price of $4.08

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)